Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine
BJU International · 2024
DOI: 10.1111/bju.16318 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift BJU International, 2024. Verfasst von Luca Afferi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Cystectomy, Deoxycytidine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: AstraZeneca Schweiz.
Abstract (Originalsprache)
Objective
To report on the surgical safety and quality of pelvic lymph node dissection (PLND) in patients treated with radical cystectomy (RC) and PLND for muscle‐invasive bladder cancer (MIBC) after neoadjuvant chemo‐immunotherapy. Patients and Methods The Swiss Group for Clinical Cancer Research (SAKK) 06/17 was an open‐label single‐arm phase II trial including 61 cisplatin‐fit patients with clinical stage (c)T2–T4a cN0–1 operable urothelial MIBC or upper urinary tract cancer. Patients received neoadjuvant cisplatin/gemcitabine and durvalumab followed by surgery. Prospective quality assessment of surgeries was performed via central review of intraoperative photographs. Postoperative complications were assessed using the Clavien–Dindo Classification. Data were analysed descriptively.
Results
A total of 50 patients received RC and PLND. All patients received neoadjuvant chemo‐immunotherapy. The median (interquartile range) number of lymph nodes removed was 29 (23–38). No intraoperative complications were registered. Grade ≥III postoperative complications were reported in 12 patients (24%). Complete nodal dissection (100%) was performed at the level of the obturator fossa (bilaterally) and of the left external iliac region; in 49 patients (98%) at the internal iliac region and at the right external iliac region; in 39 (78%) and 38 (76%) patients at the right and left presacral level, respectively.
Conclusion
This study supports the surgical safety of RC and PLND following neoadjuvant chemo‐immunotherapy in patients with MIBC. The extent and completeness of protocol‐defined PLND varies between patients, highlighting the need to communicate and monitor the surgical template.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.
- Lindenhofspital Bern, Bern, Switzerland.
- Competence Center of SAKK, Bern, Switzerland.
- Department of Urology, Kantonsspital Graubünden, Chur, Switzerland.
- Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
- Kantonsspital Baden, Baden, Switzerland.
ORCID-Profile: Luca Afferi, Sacha I Rothschild, Bernhard Kiss, Jana Musilova
Förderung
- AstraZeneca Schweiz
Zitieren
APA
Afferi, L., Spahn, M., Hayoz, S., Strebel, R. T., Rothschild, S. I., Seifert, H., Özdemir, B. C., Kiss, B., Maletzki, P., Engeler, D., Wirth, G., Hadaschik, B., Lucca, I., John, H., Sauer, A., Müntener, M., Bubendorf, L., Schneider, M., Musilova, J., …, & Swiss Group for Clinical Cancer Research (SAKK) (2024). Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine. BJU International. https://doi.org/10.1111/bju.16318
Vancouver
Afferi L, Spahn M, Hayoz S, Strebel RT, Rothschild SI, Seifert H, et al. Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine. BJU International. 2024. doi:10.1111/bju.16318
BibTeX
@article{Afferi2024,
author = {Afferi, Luca and Spahn, Martin and Hayoz, Stefanie and Strebel, Räto T and Rothschild, Sacha I and Seifert, Helge and Özdemir, Berna C and Kiss, Bernhard and Maletzki, Philipp and Engeler, Daniel and Wirth, Gregory and Hadaschik, Boris and Lucca, Ilaria and John, Hubert and Sauer, Andreas and Müntener, Michael and Bubendorf, Lukas and Schneider, Martina and Musilova, Jana and Petrausch, Ulf and Cathomas, Richard and Swiss Group for Clinical Cancer Research (SAKK), Swiss Group for Clinical Cancer Research (SAKK)},
title = {Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine},
journal = {BJU International},
year = {2024},
doi = {10.1111/bju.16318}
}
EUVIMED